Availability of early lunch for ‘Mabthera’ biosimilar in Korea
‘Truxima,’ a biosimilar antibody developed by Celltrion from ‘Mabthera Inj(foreign name: Rituxan),’ got the green light for its early domestic launch as winning a series of patent suits.
Mabthera is a treatment sold by a multinational pharmaceutical company Roche for diseases, such as lymphoma a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
